📊 TELA Key Takeaways
Is TELA Bio, Inc. (TELA) a Good Investment?
TELA Bio exhibits a critical solvency crisis with negative shareholders' equity (-5.2M) and insufficient operating cash flows (-11.2M annually) to service 55.9M in debt, creating severe financial distress risk. While strong gross margins (65.7%) and revenue growth (+15.8% YoY) indicate product viability, the company faces insolvency within 3-4 years at current burn rates unless achieving rapid profitability or securing dilutive capital.
TELA Bio, Inc. Key Strengths (TELA)
- Strong gross margin of 65.7% demonstrates product pricing power and operational efficiency in manufacturing
- Revenue growth of 15.8% YoY shows market traction and demand for surgical products
- Cash position of 39.5M provides near-term operational runway versus current burn rate
TELA Stock Risks: TELA Bio, Inc. Investment Risks
- Negative shareholders' equity of -5.2M indicates technical insolvency; liabilities exceed assets
- Operating cash burn of -11.2M annually is unsustainable with only 3.5 year runway at current rate
- Debt service impossible from operations (negative interest coverage -7.9x); refinancing risk is acute
Key Metrics to Watch
- Operating income trajectory and path to breakeven; critical to assess narrowing of -55.2% operating margin
- Operating cash flow improvement; company must achieve positive OCF to avoid forced restructuring
- Debt refinancing activity and capital raise announcements; assess dilution impact on remaining equity value
TELA Bio, Inc. (TELA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.61x current ratio provides a solid financial cushion.
TELA Profit Margin, ROE & Profitability Analysis
TELA vs Healthcare Sector: How TELA Bio, Inc. Compares
How TELA Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TELA Bio, Inc. Stock Overvalued? TELA Valuation Analysis 2026
Based on fundamental analysis, TELA Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TELA Bio, Inc. Balance Sheet: TELA Debt, Cash & Liquidity
TELA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TELA Bio, Inc.'s revenue has grown significantly by 172% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.04 indicates the company is currently unprofitable.
TELA Revenue Growth, EPS Growth & YoY Performance
TELA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.5M | -$11.3M | $-0.21 |
| Q3 2025 | $19.0M | -$8.6M | $-0.19 |
| Q2 2025 | $16.1M | -$9.9M | $-0.22 |
| Q1 2025 | $16.6M | -$5.7M | $-0.23 |
| Q3 2024 | $15.1M | -$10.4M | $-0.42 |
| Q2 2024 | $14.5M | -$10.8M | $-0.46 |
| Q1 2024 | $11.9M | -$5.7M | $-0.23 |
| Q3 2023 | $11.2M | -$10.7M | $-0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TELA Bio, Inc. Dividends, Buybacks & Capital Allocation
TELA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TELA Bio, Inc. (CIK: 0001561921)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TELA
What is the AI rating for TELA?
TELA Bio, Inc. (TELA) has an AI grade of D with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TELA's key strengths?
Claude: Strong gross margin of 65.7% demonstrates product pricing power and operational efficiency in manufacturing. Revenue growth of 15.8% YoY shows market traction and demand for surgical products.
What are the risks of investing in TELA?
Claude: Negative shareholders' equity of -5.2M indicates technical insolvency; liabilities exceed assets. Operating cash burn of -11.2M annually is unsustainable with only 3.5 year runway at current rate.
What is TELA's revenue and growth?
TELA Bio, Inc. reported revenue of $19.1M.
Does TELA pay dividends?
TELA Bio, Inc. does not currently pay dividends.
Where can I find TELA SEC filings?
Official SEC filings for TELA Bio, Inc. (CIK: 0001561921) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TELA's EPS?
TELA Bio, Inc. has a diluted EPS of $-0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TELA's fundamental grade?
Based on our AI fundamental analysis in June 2026, TELA Bio, Inc. has a D grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TELA stock overvalued or undervalued?
Valuation metrics for TELA: ROE of N/A (sector avg: 15%), net margin of -64.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TELA's AI grade for 2026?
Our dual AI analysis gives TELA Bio, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TELA's free cash flow?
TELA Bio, Inc.'s operating cash flow is $-11.2M, with capital expenditures of $119.0K. FCF margin is -59.2%.
How does TELA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -64.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 3.61 (avg: 2).